INS and metabolic dysfunction-associated steatohepatitis: J2H-1702, a novel 11β-HSD1 inhibitor, has demonstrated potential in improving insulin sensitivity, reducing inflammation, and preventing non-alcoholic steatohepatitis (NASH) in preclinical models.